Volume : 11, Issue : 04, April – 2024
Title:
A REVIEW ON LUMATEPERONE ANTI-PSYCHOTIC DRUG
Authors :
Shaik. Mahammad Shadulla , R.Jona Methusala
Abstract :
Limitations of the study include the exclusion of patients with treatment-resistant illness, imminent suicidal risk, rapid cycling, or serious comorbid psychiatric or medical illnesses, which may limit the generalizability of the findings. This study only assessed lumateperone at 42 mg/day, so dose-response characteristics cannot be established, and it did not include an active treatment arm, so comparisons with other therapies are historical. Lastly, the safety data in this study are for short-term exposure; additional studies are needed to examine long-term safety in patients with bipolar disorder. Of note, lumateperone had a favorable safety and tolerability profile in a 1-year study in patients with stable schizophrenia
Cite This Article:
Please cite this article in press Shaik. Mahammad shadulla et al., A Review On Lumateperone Anti-Psychotic Drug., Indo Am. J. P. Sci, 2024; 11 (04).
Number of Downloads : 10
References:
1. Kantrowitz JT. The Potential Role of Lumateperone-Something Borrowed? Something New? JAMA Psychiatry. 2020 Apr 01;77(4):343-344. [PubMed]
2. Vyas P, Hwang BJ, Brašić JR. An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opin Pharmacother. 2020 Feb;21(2):139-145. [PubMed]
3. Blair HA. Lumateperone: First Approval. Drugs. 2020 Mar;80(4):417-423. [PubMed]
4. Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019 Sep;29(9):971-985. [PubMed]
5. Calsolaro V, Antognoli R, Okoye C, Monzani F. The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer’s Disease. Front Pharmacol. 2019;10:1465. [PMC free article] [PubMed]
6. Snyder GL, Vanover KE, Davis RE, Li P, Fienberg A, Mates S. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. Adv Pharmacol. 2021;90:253-276. [PubMed]
7. Vraylar (cariprazine) (package insert). Madison, NJ, Allergan, 2019Google Scholar
8. Seroquel XR (quetiapine fumarate) (package insert). Wilmington, Del, AstraZeneca, 2018Google Scholar
9. Seroquel (quetiapine fumarate) (package insert). Wilmington, Del, AstraZeneca, 2016Google Scholar
10. Solmi M, Murru A, Pacchiarotti I, et al.: Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 2017; 13:757–777Crossref, Medline, Google Scholar
11. García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al.: Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 2016; 36:355–371Crossref, Medline, Google Scholar
12. Vancampfort D, Stubbs B, Mitchell AJ, et al.: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder, and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015; 14:339–347Crossref, Medline, Google Scholar
13. Snyder GL, Vanover KE, Zhu H, et al.: Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl) 2015; 232:605–621Crossref, Medline, Google Scholar
14. Snyder GL, Vanover KE, Zhu H, et al.: Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl) 2015; 232:605–621Crossref, Medline, Google Scholar
15. Vanover K, Satlin A, Durgam S, et al.: Favorable long-term safety profile of lumateperone (ITI-007): results from a 12-month open-label safety study in patients with stable symptoms of schizophrenia (poster). Schizophr Bull 2019; 45(suppl 2):S351Crossref, Google Scholar
16. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–389Crossref, Medline, Google Scholar
17. Spearing MK, Post RM, Leverich GS, et al.: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73:159–171Crossref, Medline, Google Scholar
18. Young RC, Biggs JT, Ziegler VE, et al.: A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978; 133:429–435Crossref, Medline, Google Scholar
19. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11–19Crossref, Medline, Google Scholar
20. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672–676Crossref, Medline, Google Scholar
21. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218–222Google Scholar
22. Miller MJ, Himmerich H, Kienzle B, et al.: Differentiating moderate and severe depression using the Montgomery-Åsberg depression rating scale (MADRS). J Affect Disord 2003; 77:255–260Crossref, Medline, Google Scholar
23. Loebel A, Cucchiaro J, Silva R, et al.: Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J
24. Durgam S, Earley W, Lipschitz A, et al.: An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry 2016; 173:271–281Link, Google Scholar
25. Suppes T, Hirschfeld RM, Vieta E, et al.: Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008; 9:198–211Crossref, Medline, Google Scholar
26. Correll CU: From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010; 25(suppl 2):S12–S21Crossref, Medline, Google Scholar